Claims of ‘miracle cures’ for autism in the press and on the Internet bring new pressures to bear on parents of children with autism, and the professionals who care for them. Between a third and a half of people with autism in America are receiving some psychotropic medication. Despite recent advances in paediatric psychopharmacology, there is no proof that any medication can target the primary social impairments that characterize autism. The article discusses the evidence behind two approaches to psychopharmacological management in children with autism. The first approach selects certain target symptoms such as resistance to change, ritualistic/compulsive behaviours, hyperactivity, aggressive behaviours and sleep problems. The evidence for the effectiveness of agents including stimulants, anti- depressants, and melatonin when used to treat these symptoms is appraised. The second approach attempts to treat or cure the primary social impairment underlying autism. The evidence for the effectiveness of agents including naltrexone, fenfluramine and secretin is appraised. Early reports in this field have generated false hope, and the need for well-designed larger multicentre trials is emphasized.
AMAN, M.G. , VAN BOURGONDIEN, M.E., WOLFORD, P.L. & SAPHARE, G. (1995) ‘Psychotropic and Anticonvulsant Drugs in Subjects with Autism: Prevalence and Patterns of Use’, Journal of the American Academy of Child & Adolescent Psychiatry34: 1672-1681.
2.
AWAD, G.A. (1996) ‘The Use of Selective Serotonin Reuptake Inhibitors in Young Children with Pervasive Developmental Disorders: Some Clinical Observations’, Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie41: 361-366.
3.
BUITELAAR, J.K. , DEKKER, M.E,. VAN REE, J.M. & VAN ENGLAND, H. (1996) ‘A Controlled Trial with ORG 2766, an ACTH-(4-9) Analog, in 50 Relatively Able Children with Autism’, European Neuropsychopharmacology6: 13-19.
4.
CAMPBELL, M. (1988) ‘Fenfluramine Treatment of Autism’, Journal of Child Psychology & Psychiatry29: 1-10.
5.
CAMPBELL, M. (1999) ‘Lithium in Hospitalized Aggressive Children with Conduct Disorders: A Double-blind and Placebo-controlled Study’, Journal of the American Academy of Child and Adolescent Psychiatry34(4): 445-453.
6.
CAMPBELL, M.ET AL. (1993) ‘Naltrexone in Autistic Children: Behavioural Symptoms and Attentional Learning’, Journal of the American Academy of Child and Adolescent Psychiatry32(6): 1283-1291.
7.
CAMPBELL, M. , ANDERSON, L.T., MEIER, M., COHEN, I., SMALL, A.M., et al. (1978) ‘A Comparison of Haloperidol and Behaviour Therapy and their Interaction in Autistic Children’, Journal of the American Academy of Child & Adolescent Psychiatry27: 640-655.
8.
CAMPBELL, M. , SCHOPLER, E., CUEVA, J.E. & HALLIN, A. (1996) ‘Treatment of Autistic Disorder’, Journal of the American Academy of Child & Adolescent Psychiatry35: 134-143.
9.
CAMPBELL, M. , ADAMS, P., PERRY, R.et al. (1998) ‘Tardive and Withdrawal Dyskinesia in Autistic Children: A Prospective Study’, Psychopharmacology Bulletin24: 251-255.
10.
CHAPPELL, P.B. , LECKMAN, J.F., & RIDDLE, M. (1995) ‘The Pharmacological Treatment of Tic Disorders’, Child and Adolescent Psychiatric Clinics of North America4: 197-216.
11.
CIARANELLO, A.L. & CIARANELLO, R.D. (1995) ‘The Neurobiology of Infantile Autism’, Annual Review of Neuroscience18: 101-128.
12.
CONNORS, S.L. & CROWELL, D.E. (1999) ‘Secretin and Autism: The Role of Cysteine [4]’, Journal of the American Academy of Child & Adolescent Psychiatry38: 795-796.
13.
COOK, E.H. & LEVENTHAL, B.L. (1996) ‘The Serotonin System in Autism’, Current Opinion in Pediatrics8: 348-384.
14.
COOK, E.H. , ROWLETT, R., JASELSKIS, C.A. & LEVENTHAL, B.L. (1992) ‘Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation’, Journal of the American Academy of Child & Adolescent Psychiatry31: 739-745.
15.
CRAFT, M. , ISMAIL, I.A., KRISHNAUMURTI, D., MATHEWS, J.et al. (1987) ‘Lithium in the Treatment of Aggression in Mentally Handicapped Patients: A Double Blind Trial’, British Journal of Psychiatry150: 685-689.
16.
DELONG, G.R. , TEAGE, L.A. & KARMAN, M.M. (1998) ‘Effects of Fluoxetine Treatment in Young Children with Ideopathic Autism’, Developmental Medicine & Child Neurology40: 551-562.
17.
DURAND, V.M. & CARR, E.G. (1991) ‘Functional Communication Training to Reduce Challenging Behavior: Maintenance and Application in New Settings’, Journal of Applied Behavior Analysis24: 251-264.
18.
EVANS, R.W. , CLAY, T.H. & GUALTIERI, C.T. (1999) ‘Carbamazepine in Pediatric Psychiatry’, Journal of the American Academy of Child & Adolescent Psychiatry26: 2-8.
19.
FANKHAUSER, M.P. , KARAMANCHI, V.C., GERMAN, M.L.et al. (1992) ‘A Double Blind Placebo-Controlled Study of the Efficacy of Transdermal Clonidine in Autism’, Journal of Clinical Psychiatry77-82.
20.
FELDMAN, H.M. , KOLMEN, B.K., GONZAGA, A.M. & ALDA, M. (1999) ‘Naltrexone and Communication Skills in Young Children with Autism’, Journal of the American Academy of Child & Adolescent Psychiatry38: 587-593.
21.
FINDLING, R.L. , MAXWELL, K., SCOTESE-WOJTILA, L., HUANG, J. & WITNITZER, M. (1997) ‘High-Dose Pyridoxine and Magnesium Administration in Children with Autistic Disorder: An Absence of Salutary Effects in a Double-Blind, Placebo Controlled Study’, Journal of Autism and Developmental Disorder27: 467-478.
22.
FLAMENT, M.F. , RAPOPORT, J.L., BERG, C.B.et al. (1999) ‘Clompiramine Treatment of Childhood Obsessive-Compulsive Disorder: A Double-Blind Controlled Study.’, Archives of General Psychiatry42: 977-983.
23.
GILLBERG, C. (1995) ‘Endogenous Opioids and Opiate Antagonists in Autism: Brief Review of Empirical Findings and Implications for Clinicians’, Developmental Medicine & Child Neurology37: 239-245.
24.
GORDON, C.T. , STATE, R.C., NELSON, J.E., HAMBURGER, S.D. & RAPOPORT, J.L. (1993) ‘A Double-Blind Comparison of Clomipramime, Desipramine, and Placebo in the Treatment of Autistic Disorder’, Archives of General Psychiatry46: 441-447.
25.
GRINGRAS, P. & MCNICHOLAS, F. (1999) ‘Developing Rational Protocols for Paediatric Psychopharmacological Prescribing’, Child: Care, Health and Development25: 223-233.
26.
GUYATT, G.H. , SULLIVAN, M.J.J., FALLEN, E.et al. (1990) ‘Clinical Usefulness of N of 1 Randomised Control Trials: Three Year Experience’, Annals of Internal Medicine112: 293-299.
27.
HORVATH, K. , STEFANATOS, G., SOKOLSKI, K.N., WACHTEL, R.et al. (1998) ‘Improved Social and Language Skills after Secretin Administration in Patients with Autistic Spectrum Disorders’, Journal of the Association for Academic Minority Physicians9: 9-15.
28.
JAN, J.E. (1994) ‘The Treatment of Sleep Disorders with Melatonin’, Dev. Med. Child Neurology36(2): 97-107.
29.
JASELSKIS, C.A. , COOK, E.H., FLETCHER, K.E. & LEVENTHAL, B.L. (1992) ‘A Double-Blind, Placebo Controlled Study of the Efficacy of Transdermal Clonidine in Autism’, Journal of Clinical Psychopharmacology12: 77-82.
30.
MARSH, J. , BIEDERMAN, J. & HOOK, E. (1998) ‘Sertraline in Children and Adolescents with OCD’, Journal of the American Medical Association280: 752-756.
31.
MARTIN, M. , SCAHILL, L., LAWRENCE, M.S.N., KLIN, A.M.I. & VOLKMAR, F.R. (1999) ‘Higher-Functioning Pervasive Developmental Disorders: Rates and Patterns of Psychotropic Drug Use’, Journal of the American Academy of Child & Adolescent Psychiatry38: 923-931.
32.
MCDOUGLE, C.J. (1997) ‘Psychopharmacology’, in: D.J. COHEN & F.R. VOLKMAR (eds) Handbook of Autism and Pervasive Developmental Disorders, 2nd edn, pp. 707-729. New York: Wiley.
33.
MCDOUGLE, C.J. (1998) ‘A Double-blind Placebo-controlled Study of Risperidone in Adults with Autistic Disorders and Other Pervasive Developmental Difficulties’, Archives of General Psychiatry55(7): 633-641.
34.
MCDOUGLE, C.J. , FLEISCHMANN, R.L., EPPERSON, C.N., WASYLINK, S., LECKMAN, J.F. & PRICE, L.H. (1995) ‘Risperidone Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: Three Cases’, Journal of Clinical Psychiatry56: 526-528.
35.
MCDOUGLE, C.J. , NAYLOR, S.T., COHEN, D.J., VOLKMAR, F.R., HENINGER, G.R. & PRICE, L.H. (1996) ‘A Double-Blind, Placebo-Controlled Study of Fluvoxamine in Adults with Autistic Disorder’, Archives of General Psychiatry53: 1001-1008.
36.
NICOLSON, R. , AWAD, G. & SLOMAN, L. (1998) ‘An Open Trial of Risperidone in Young Autistic Children’, Journal of the American Academy of Child & Adolescent Psychiatry37: 372-376.
37.
PANKSEPP, J. (1980) ‘Endogenous Opiods and Social Behaviour’, Neurosc. Biobehav. Review4(4): 473-487.
38.
PANKSEPP, J. & LENSING, P. (1991) ‘Brief Report: A Synopsis of an Open-Trial of Naltrexone Treatment of Autism with Four Children’, Journal of Autism and Developmental Disorders, 21: 243-249.
39.
PFEIFFER, S.I. , NORTON, J., NELSON, L. & SHOTT, S. (1995) ‘Efficacy of Vitamin B6 and Magnesium in the Treatment of Autism: A Methodology Review and Summary of Outcomes’, Journal of Autism & Developmental Disorders25: 480-493.
40.
PIAZZA (1999) ‘Review of Strategies for Treating Sleep Problems in Persons with Severe or Profound Mental Retardation or Multiple Handicap’, American Journal of Mental Retardation104(2): 170-186.
41.
RICHDALE (1999) ‘Sleep Problems in Autism: Prevalence, Cause and Intervention’, Dev. Med. Child Neurology41(1): 60-66.
42.
RIDDLE, M. , KING, R.A. & HARDIN, M. (1991) ‘Behavioural Side-Effects with Fluoxetine in Children and Adolescents’, Journal of Child & Adolescent Psychopharmacology4: 31-41.
43.
RIMLAND, B. & EDELSON, S.M. (1996) ‘Brief Report: Alternative Approaches to the Development of Effective Treatments for Autism’, Journal of Autism and Developmental Disorder25: 237-241.
44.
RIVITO, E.R. , FREEMAN, B.J., GELLER, E.et al. (1983) ‘Effects of Fenfluramine on 14 Outpatients with the Syndrome of Autism’, Journal of the American Academy of Child Psychiatry22: 549-558.
45.
SACKETT, D.L. , HAYNES, R.B. & TUGWELL, P. (1999) Clinical Epidemiology: A Basic Science for Clinical Medicine, 2nd edn.Boston, MA: Little, Brown.
46.
SANDLER, A.D. , SUTTON, K.A., DEWEESE, J., GIRARDI, M.A., SHEPPARD, V. & BODFISH, J.W. (1999) ‘A Double-Blind, Placebo Controlled Study of Synthetic Human Secretin in the Treatment of Autism and Pervasive Developmental Disorder’, New England Journal of Medicine341: 1801-1806.
47.
SANTOSH, P.J. & BAIRD, G. (1999) ‘Psychopharmacotherapy in Children and Adults with Intellectual Disability’, The Lancet354: 231-240.
48.
SCHUSTER, C. , LEWIS, M. & SEIDEN, L. (1986) ‘Fenfluramine: Neurotoxicity’, Psychopharmacology Bulletin22: 148-151.
49.
STEINGARD, R.J. , ZIMNITZKY, B., DEMASO, D.R., BAUMAN, M.L. & BUCCI, J.P. (1997) ‘Sertraline Treatment of Transition-Associated Anxiety and Agitation in Children with Autistic Disorder’, Journal of Child & Adolescent Psychopharmacology7: 9-15.
50.
TSAI, L.Y. (1996) ‘Comorbid Psychiatric Disorder of Autistic Disorder’, Journal of Autism and Developmental Disorders, 26: 159-163.
51.
TSAI, L.Y. (1999) ‘Medical Treatment’, in D.E. BERKELL ZAGER (ed.) Autism: Identification, Education and Treatment, 2nd edn, pp. 199-257. Mahwah, NJ: Lawrence Erlbaum.
52.
TSAI, L.Y. & GHAZIUDDIN, M. (1996) ‘Autistic Disorder’, in J. WEINER (ed.) The Comprehensive Textbook of Child and Adolescent Psychiatry, 2nd edn, pp. 219-254. Washington, DC: American Psychiatric Press.
53.
VOLKMAR, F.R. (1999) ‘Lessons from Secretin’, New England Journal of Medicine341: 1842-1843.
54.
VOLKMAR, F.R. , PAUL, R., COHEN, D.J.et al. (1983) ‘Irritability in Autistic Children Treated with Fenfluramine’, New England Journal of Medicine309: 187.
55.
WACKER, D.P. , STEEGE, M.W., NORTHUP, J., SASSO, G., BERG, W., REIMERS, T., COOPER, L., CIGRAND, K. & DONN, L. (1990) ‘A Component Analysis of Functional Communication Training Across Three Topographies of Severe Behaviour Problems’, Journal of Applied Behaviour Analysis23: 417-429.
56.
WALKUP, J. (1998) ‘Fluvoxamine for Childhood OCD: Long-Term Treatment’, paper presented at the International Association of Child Psychology and Psychiatry Meeting, Stockholm.
57.
ZHDANOVA, I.V. , WURTMAN, R.J. & WAGSTAFF, J. (1999) ‘Effects of a Low Dose of Melatonin on Sleep in Children with Angelman Syndrome’, Journal of Pediatric Endocrinology and Metabolism12: 57-67.
